NCT01829997View on ClinicalTrials.gov

Assessment of nanOss Bioactive 3D in the Posterolateral Spine

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Degenerative Disc DiseaseSpinal StenosisSpondylolisthesis
Interventions
DEVICE

nanOss Bioactive 3D BVF

nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.

Trial Locations (4)

10003

Hospital for Joint Disease, New York

10021

Hospital for Special Surgery, New York

29425

MUSC Neurosurgery & Spine Services, Charleston

53212

Milwaukee Spinal Specialists, Glendale

Sponsors
All Listed Sponsors
lead

Pioneer Surgical Technology, Inc.

INDUSTRY

NCT01829997 - Assessment of nanOss Bioactive 3D in the Posterolateral Spine | Biotech Hunter | Biotech Hunter